Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled. All patients received alfuzosin 10 mg once daily for 24 weeks and were asked to complete the IPSS test and Male Sexual Health Questionnaire at weeks 0 (baseline), 1, 4, 12, and 24. Other assessments included the International Index of Erectile Function-five-item version (range of scores: 5-25), as well as onset of action and peak urinary flow rate (Q(max)). From September 2006 to May 2008, 279 patients were enrolled from nine centers in Taiwan. At 24 weeks, alfuzosin effectively improved LUTS and quality of life, as demonstrated by a reduction in the IPSS total score (17.3 vs. 9.9, p < 0.001) and the IPSS bother score (3.8 vs. 2.5, p < 0.001). The majority (85%) of patients perceived an improvement of urinary symptoms within 1 month of administration. In patients with an International Index of Erectile Function-five-item version score of ≤16, alfuzosin significantly improved erectile disorder and satisfaction subscores at each time point (p ≤ 0.02). Prolonged-release alfuzosin effectively improved LUTS, quality of life, erectile function, and sexual satisfaction in men with BPH and mild to severe erectile dysfunction. Alfuzosin is an effective treatment option for the management of patients with BPH/LUTS and concomitant sexual dysfunction.
Division of Urology, Department of Surgery, Shin Kong WHS Memorial Hospital, Fu Jen Catholic University School of Medicine, Taipei, Taiwan.
Thomas I S
TI
Hwang
Sheng-Hsien
SH
Chu
Mao-Sheng
MS
Lin
Chih-Shou
CS
Chen
Liang-Ming
LM
Lee
Hong-Chiang
HC
Chang
Shauh-Der
SD
Yeh
Wen-Hsiang
WH
Chen
Po-Hui
PH
Chiang
D000368:Aged; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy* / Q000503:physiopathology; D013624:Taiwan; D016896:Treatment Outcome
D011799:Quinazolines; C047638:alfuzosin